Driving affordability and choice with HUMIRA and biosimilars

April 1, 2024

The cost of specialty medications is rising faster than any other component of health care. This is driven largely by biologic medicines for inflammatory conditions and new treatments for cancer and rare diseases.

Because of this, we regularly assess biosimilars — which have no clinically meaningful differences but offer savings potential — to determine which are appropriate for our formularies. When assessing a biosimilar, we consider many factors including:

  • Clinical safety.
  • Efficacy data.
  • Indications approved by the U.S. Food and Drug Administration.
  • The ability of the biosimilar to meet market demand.

Our approach to HUMIRA® and alternative biosimilars

We offer HUMIRA and select biosimilars to HUMIRA on the Cigna Healthcare preferred drug list. By co-preferring certain biosimilars alongside HUMIRA, we are able to:

  • Expand choice and drive affordability for anti-inflammatory drugs, the costliest therapeutic class.
  • Demonstrate our long-standing support and advancement of biosimilars as a pathway to more choice for providers and customers.
  • Increase access to life-changing specialty medications.
  • Potentially lower health care costs.

Additional information

A list of covered biosimilars is available on the Cigna for Health Care Professionals website (CignaforHCP.com) > Get questions answered: Resource > Pharmacy Resources > Cigna’s Prescription Drug Lists: View Documents.

How are we doing?

Please let us know what you think of the Provider Newsroom information and news.

Contact Us